Postoperative Analgesic Effect of Nefopam

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02561494

Enrollment

Registered

2015-09-28

Start date

2015-06-30

Completion date

2016-08-31

Last updated

2016-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasms

Brief summary

Nefopam will be administered to the patients undergoing laparoscopic gastrectomy under the total intravenous anesthesia (TIVA). The investigators will evaluate whether the nefopam can decrease the total amount of remifentanil administered during the operation, which will reduce the acute opioid tolerance and following consumption of fentanyl during postoperative period.

Interventions

DRUGNefopam

DRUGSaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Early or advanced gastric cancer

Exclusion criteria

* Refusal * Use of preoperative analgesic drugs * Pregnancy * Recurred gastric cancer * Seizure * Cardiac disease * Monoamine oxidase inhibitor * Urologic disease * Previous intrabdominal surgery * Body mass index \> 30 or \< 16

Design outcomes

Primary

Measure	Time frame
Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day	postoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day

Secondary

Measure	Time frame
Change of the pain score from postoperative 6 h to postoperative 5 day	postoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026